Showing results (31-40 of 591) with videos related to
Sort By:
Pageof 60
Revue Des Maladies Respiratoires|November 26, 2008
[Early-stage NSCLC. The renaissance of radiotherapy in early-stage non-small cell lung cancer]N Girard, F MornexCancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 22, 2001
[Radiotherapy of cancers of the pancreas and extrahepatic biliary tree. Gross tumor volume (GTV). Clinical target volume (CTV)]D Atlan, F MornexCancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|January 18, 2011
[External radiotherapy for hepatocellular carcinoma]N Girard, F MornexCancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|July 2, 2010
[Normal tissue tolerance to external beam radiation therapy: lung]C Ortholan, F MornexCancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|September 1, 2019
[Stereotactic radiotherapy of stage I non-small cell lung cancer. State of the art in 2019 and recommendations: Stereotaxy as an alternative to surgery?]H Kaiss, F MornexCancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|January 29, 1999
[Concomitant chemoradiotherapy in the therapeutic strategy of adenocarcinoma of the exocrine pancreas and stomach]F Mornex, B ChauffertRevue Des Maladies Respiratoires|February 22, 2008
[Quality criteria of thoracic radiotherapy. Application to clinical research]N Girard, F MornexRevue Des Maladies Respiratoires|February 3, 2007
[Stage IIIB non-small cell lung cancer. Optimization of radiotherapy in lung cancer: some interesting questions to be solved]N Girard, F MornexCancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|September 6, 2015
[Follow-up after stereotactic body radiation therapy for liver tumours: A review of the literature and recommendations]G Janoray, F MornexCancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 29, 2017
[Stereotactic body radiation therapy for hepatic malignancies: Organs at risk, uncertainties margins, doses]T Lacornerie, E Rio, M-A MahéPageof 60